Results from a prospective multicenter study evaluate whether the integrated 31-gene expression profile test can reduce unnecessary sentinel lymph node biopsies in patients with cutaneous melanoma.
A retrospective study evaluates osimertinib outcomes in patients with EGFR-mutant NSCLC who developed T790M mutation and EGFR amplification after first-generation EGFR-TKI resistance.
This analysis from the MONARCH 2 trial examines whether simple blood markers like neutrophil-to-lymphocyte ratio and absolute lymphocyte count are linked to outcomes in advanced hormone receptor–positive, HER2-negative breast cancer.
A multicenter cohort study evaluates whether chest wall perforator flap reconstruction can safely support breast-conserving surgery and reduce mastectomy rates in breast cancer patients.
Results from a pooled analysis explore whether acalabrutinib can provide durable disease control for patients with high-risk genetic features in chronic lymphocytic leukemia.
New findings evaluate whether adding durvalumab after chemoradiotherapy can improve survival outcomes for patients with locoregional recurrence of completely resected non-small cell lung cancer.
This window-of-opportunity study evaluates the biologic activity, dosing, and tolerability of imlunestrant given before surgery in patients with newly diagnosed ER-positive, HER2-negative early breast cancer.
Findings from this study assess how a combined genetic and clinicopathologic approach may refine predictions of sentinel lymph node positivity in melanoma.
Results from the EMBER study examine how the oral selective estrogen receptor degrader imlunestrant performs alone and in combination with targeted therapies in advanced ER-positive, HER2-negative breast cancer.
Updated findings assess whether osimertinib alone can provide meaningful intracranial disease control for patients with EGFR-mutant NSCLC and untreated brain metastases.
For patients with chronic lymphocytic leukemia who have already received treatment, results from the ELEVATE-RR trial help clarify the safety differences between acalabrutinib and ibrutinib.
New four-year data from the ASCEND trial show how acalabrutinib compares with commonly used combination therapies for people with relapsed or refractory chronic lymphocytic leukemia.
©2026 Oncology Matrix. All Rights Reserved.
